Clinical Trial: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428473) titled 'A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)' on Feb. 01.

Brief Summary: STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. By turning off this gene, STX-1150 aims to keep more LDL receptors active, resulting in lower LDL-C levels.

STX-1150 is comprised of an epigenic modulator mRNA and single guide RNA delivered in lipid nanoparticle for IV infusion. The mRNA produces a protein that switches off the PCSK9 gene without altering the DNA sequence. This...